These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 34453903)

  • 1. MMP inhibition attenuates hypertensive eccentric cardiac hypertrophy and dysfunction by preserving troponin I and dystrophin.
    Parente JM; Blascke de Mello MM; Silva PHLD; Omoto ACM; Pernomian L; Oliveira IS; Mahmud Z; Fazan R; Arantes EC; Schulz R; Castro MM
    Biochem Pharmacol; 2021 Nov; 193():114744. PubMed ID: 34453903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats.
    Castro MM; Rizzi E; Figueiredo-Lopes L; Fernandes K; Bendhack LM; Pitol DL; Gerlach RF; Tanus-Santos JE
    Atherosclerosis; 2008 Jun; 198(2):320-31. PubMed ID: 18054360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type I collagen proteolysis by matrix metalloproteinase-2 contributes to focal adhesion kinase activation and vascular smooth muscle cell proliferation in the aorta in early hypertension.
    de Oliveira Neves VG; Blascke de Mello MM; Rodrigues D; Pernomian L; de Oliveira IS; Parente JM; Arantes EC; Tostes RC; Castro MM
    Vascul Pharmacol; 2023 Oct; 152():107211. PubMed ID: 37607602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. β1-Adrenergic blockers exert antioxidant effects, reduce matrix metalloproteinase activity, and improve renovascular hypertension-induced cardiac hypertrophy.
    Rizzi E; Guimaraes DA; Ceron CS; Prado CM; Pinheiro LC; Martins-Oliveira A; Gerlach RF; Tanus-Santos JE
    Free Radic Biol Med; 2014 Aug; 73():308-17. PubMed ID: 24933619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Matrix metalloproteinase (MMP)-2 activation by oxidative stress decreases aortic calponin-1 levels during hypertrophic remodeling in early hypertension.
    Blascke de Mello MM; Parente JM; Schulz R; Castro MM
    Vascul Pharmacol; 2019 May; 116():36-44. PubMed ID: 30339939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verapamil decreases calpain-1 and matrix metalloproteinase-2 activities and improves hypertension-induced hypertrophic cardiac remodeling in rats.
    Mendes AS; Blascke de Mello MM; Parente JM; Omoto ACM; Neto-Neves EM; Fazan R; Tanus-Santos JE; Castro MM
    Life Sci; 2020 Mar; 244():117153. PubMed ID: 31830479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix Metalloproteinase-2 Activity is Associated with Divergent Regulation of Calponin-1 in Conductance and Resistance Arteries in Hypertension-induced Early Vascular Dysfunction and Remodelling.
    Parente JM; Pereira CA; Oliveira-Paula GH; Tanus-Santos JE; Tostes RC; Castro MM
    Basic Clin Pharmacol Toxicol; 2017 Oct; 121(4):246-256. PubMed ID: 28374979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MMP inhibitors attenuate doxorubicin cardiotoxicity by preventing intracellular and extracellular matrix remodelling.
    Chan BYH; Roczkowsky A; Cho WJ; Poirier M; Sergi C; Keschrumrus V; Churko JM; Granzier H; Schulz R
    Cardiovasc Res; 2021 Jan; 117(1):188-200. PubMed ID: 31995179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxycycline ameliorates 2K-1C hypertension-induced vascular dysfunction in rats by attenuating oxidative stress and improving nitric oxide bioavailability.
    Castro MM; Rizzi E; Ceron CS; Guimaraes DA; Rodrigues GJ; Bendhack LM; Gerlach RF; Tanus-Santos JE
    Nitric Oxide; 2012 Mar; 26(3):162-8. PubMed ID: 22327038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling.
    Castro MM; Rizzi E; Prado CM; Rossi MA; Tanus-Santos JE; Gerlach RF
    Matrix Biol; 2010 Apr; 29(3):194-201. PubMed ID: 19969080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease.
    Ahmed SH; Clark LL; Pennington WR; Webb CS; Bonnema DD; Leonardi AH; McClure CD; Spinale FG; Zile MR
    Circulation; 2006 May; 113(17):2089-96. PubMed ID: 16636176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats.
    Martinez ML; Castro MM; Rizzi E; Fernandes K; Demacq C; Bendhack LM; Gerlach RF; Tanus-Santos JE
    Eur J Pharmacol; 2008 Sep; 591(1-3):224-30. PubMed ID: 18634778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The hydrogen sulfide donor 4-carboxyphenyl-isothiocyanate decreases blood pressure and promotes cardioprotective effect through reduction of oxidative stress and nuclear factor kappa B/matrix metalloproteinase (MMP)-2 axis in hypertension.
    Pernomian L; Blascke de Mello MM; Parente JM; Sanches-Lopes JM; Tanus-Santos JE; Parreiras E Silva LT; Antunes-Rodrigues J; da Conceição Dos Santos R; Elias LLK; Fabro AT; Silva CAA; Fazan R; de Castro MM
    Life Sci; 2024 Aug; 351():122819. PubMed ID: 38857651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doxycycline ameliorates ischemic and border-zone remodeling and endothelial dysfunction after myocardial infarction in rats.
    Camp TM; Tyagi SC; Aru GM; Hayden MR; Mehta JL; Tyagi SC
    J Heart Lung Transplant; 2004 Jun; 23(6):729-36. PubMed ID: 15366434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Doxycycline reduces cardiac matrix metalloproteinase-2 activity but does not ameliorate myocardial dysfunction during reperfusion in coronary artery bypass patients undergoing cardiopulmonary bypass.
    Schulze CJ; Castro MM; Kandasamy AD; Cena J; Bryden C; Wang SH; Koshal A; Tsuyuki RT; Finegan BA; Schulz R
    Crit Care Med; 2013 Nov; 41(11):2512-20. PubMed ID: 23928836
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Nuclear Factor kappaB Inhibitor Pyrrolidine Dithiocarbamate Prevents Cardiac Remodelling and Matrix Metalloproteinase-2 Up-Regulation in Renovascular Hypertension.
    Cau SB; Guimaraes DA; Rizzi E; Ceron CS; Gerlach RF; Tanus-Santos JE
    Basic Clin Pharmacol Toxicol; 2015 Oct; 117(4):234-41. PubMed ID: 25816715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contribution of plasma matrix metalloproteinases to development of left ventricular hypertrophy and diastolic dysfunction in hypertensive subjects.
    Saglam M; Karakaya O; Esen AM; Barutcu I; Dogan S; Karavelioglu Y; Karapinar H; Akgun T; Esen O; Ozdemir N; Turkmen S; Kaymaz C
    Tohoku J Exp Med; 2006 Feb; 208(2):117-22. PubMed ID: 16434834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension.
    Castro MM; Rizzi E; Rodrigues GJ; Ceron CS; Bendhack LM; Gerlach RF; Tanus-Santos JE
    Free Radic Biol Med; 2009 May; 46(9):1298-307. PubMed ID: 19248829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metalloproteinase Inhibition Protects against Reductions in Circulating Adrenomedullin during Lead-induced Acute Hypertension.
    Nascimento RA; Mendes G; Possomato-Vieira JS; Gonçalves-Rizzi VH; Kushima H; Delella FK; Dias-Junior CA
    Basic Clin Pharmacol Toxicol; 2015 Jun; 116(6):508-15. PubMed ID: 25308714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The complex regulation of tanshinone IIA in rats with hypertension-induced left ventricular hypertrophy.
    Pang H; Han B; Yu T; Peng Z
    PLoS One; 2014; 9(3):e92216. PubMed ID: 24647357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.